ISO 17664 Reprocessing Validation for Reusable Medical Devices

Why Reprocessing Validation Matters for Reusable Devices

Reusable medical devices — from arthroscopic shavers to endoscopes to surgical forceps — must be reprocessed between each patient use. When reprocessing instructions are inadequate or unvalidated, residual blood, tissue, and microbial contamination can survive disinfection or sterilization, causing healthcare-associated infections (HAIs) and adverse patient outcomes.

FDA has identified reprocessing as one of three areas where its expectations frequently diverge from other regulators (alongside biocompatibility and cybersecurity). Even if a device is already accepted in other regions, additional reprocessing testing may be required for US market entry.

This guide covers the full reprocessing validation lifecycle for reusable medical devices: applicable standards, FDA and EU MDR expectations, validation study design, worst-case device selection, IFU content, and submission evidence requirements.

Applicable Standards and Regulatory Framework

ISO 17664 Series

The ISO 17664 series is the primary international framework for reprocessing information. It was restructured in 2021 into two parts:

Critical devices enter normally sterile tissue (e.g., surgical instruments, implants, arthroscopes). Semi-critical devices contact mucous membranes or non-intact skin (e.g., endoscopes, laryngoscope blades). Non-critical devices contact intact skin only (e.g., stethoscopes, hospital beds).

Key Supporting Standards

FDA Guidance

FDA's "Reprocessing Medical Devices in Health Care Settings: Validation Methods and Labeling" (March 2015, amended June 2017) provides specific recommendations for premarket submissions. This guidance applies to all 510(k), PMA, HDE, De Novo, and IDE submissions involving reusable devices — including devices that are 510(k)-exempt (which are not exempt from labeling or QMSR requirements).

EU MDR Requirements

EU MDR Annex I GSPR 11.1–11.4 requires that devices be designed and manufactured to allow safe reprocessing. Specifically:

• Instructions must explain any pre-treatment or reprocessing required (GSPR 11.1(i))

• If supplied non-sterile, sterilization instructions must be provided (GSPR 11.1(m))

• Reprocessing instructions must include validated methods with appropriate parameters (GSPR 11.4)

• ISO 17664-1 and ISO 17664-2 are harmonized for demonstrating conformity with these requirements

The 10-Step Reprocessing Process

ISO 17664-1:2021 specifies that manufacturers must provide instructions covering the following activities, where applicable:

ISO 17664-2 (non-critical devices) covers a subset: preparation, cleaning, disinfection, drying, inspection/maintenance, packaging, storage, and transportation — without sterilization.

Validation Study Design

General Principles

Validation studies must demonstrate that the reprocessing procedure, when followed as written, consistently produces a device safe for reuse. The FDA and ISO standards require a worst-case scenario approach:

• Least rigorous implementation of the process (minimum times, temperatures, concentrations)

• Most challenging device configuration (assembled, with lumens, hinges, mated surfaces)

• Greatest degree of foreseeable contamination (clinically relevant soil load)

Cleaning Validation

Cleaning validation must demonstrate that the recommended cleaning procedure removes organic and inorganic soil to acceptable levels.

Soil selection: ASTM F3208-20 provides guidance for selecting test soils. Common soils include:

• Coagulated blood (protein, hemoglobin)

• Artificial soil formulations (protein, carbohydrate, lipid components)

• Inorganic soils (talc, barium sulfate)

Acceptance criteria (per ANSI/AAMI ST98:2022):

Sample size: A minimum of 3 devices per cleaning method is standard, tested over multiple cycles (typically 3–5 replicates per device). The total number of reprocessing cycles validated should support the claimed device lifetime.

Disinfection Validation

Disinfection can be thermal (automated, using washer-disinfectors per ISO 15883) or chemical (manual immersion).

A₀ value is the equivalent time at 80°C required to achieve a given level of thermal disinfection. An A₀ of 600 is typical for semi-critical devices; A₀ of 3000 is used for critical devices where sterilization follows.

Sterilization Validation

For critical devices, sterilization validation follows standard sterilization validation methods:

Sterilization validation typically requires:

• Half-cycle approach (demonstrating sterility at half the exposure parameters)

• Biological indicators (e.g., Geobacillus stearothermophilus for steam)

• Maximum device load configuration

• A minimum Sterility Assurance Level (SAL) of 10⁻⁶

Biocompatibility After Reprocessing

ISO 10993-1 requires that biocompatibility be assessed in the ready-to-use state — meaning after the maximum number of reprocessing cycles. Residual cleaning chemicals, disinfectants, or sterilant residues must be evaluated:

Worst-Case Device Family Selection

When a manufacturer offers multiple devices that are reprocessed using the same method, a device family approach can reduce testing burden. The worst-case representative device should be selected based on:

A documented rationale must support the selection of the worst-case device. The rationale should address each factor above and explain why the selected device represents the most challenging reprocessing scenario for the entire family.

IFU Content Requirements

ISO 17664-1:2021 requires the following content in reprocessing instructions:

Required Information

1. General information: Device identification, manufacturer contact

2. Point-of-use treatment: Immediate actions after use to prevent soil drying

3. Preparation before cleaning: Disassembly instructions, transport

4. Cleaning: Step-by-step instructions with:

   • Equipment and materials (specific brands or generic equivalents)

   • Process parameters (time, temperature, concentration)

   • Warnings and precautions

5. Disinfection: Method, parameters, and endpoints

6. Drying: Method and parameters

7. Inspection and maintenance: What to inspect, acceptance criteria

8. Packaging: Packaging materials compatible with sterilization

9. Sterilization: Validated method, cycle parameters

10. Storage: Conditions, shelf life

11. Transportation: Requirements for maintaining sterility

12. Limitations: Maximum number of reprocessing cycles

FDA-Specific Expectations

FDA's 2015 guidance adds several expectations that go beyond ISO 17664:

FDA's partial recognition of ISO 17664-1 (excluding Clause 6.6.1.1) is specifically because this clause conflicts with FDA's guidance on reprocessing validation. Manufacturers submitting to FDA should follow the FDA guidance as the primary document and use ISO 17664 as a complementary framework.

Submission Evidence

FDA 510(k) / PMA Submissions

EU MDR Technical Documentation

Lifetime and Functional Performance Validation

Reprocessing validation is not limited to a single cycle. EU MDR and FDA expect manufacturers to demonstrate that the device maintains its safety and performance throughout its intended lifetime.

This requires:

The number of reprocessing cycles validated defines the maximum number of reuses. If a manufacturer claims 50 reuses, validation must cover at least 50 complete reprocessing cycles.

Common Deficiencies and How to Avoid Them

Decision Tree: Which Validation Path Applies?

Is the device reusable?
├── No → Reprocessing validation not applicable
│         (single-use labeling required)
└── Yes → Does it contact sterile tissue or mucous membranes?
    ├── Yes (critical/semi-critical) → ISO 17664-1 applies
    │   ├── Cleaning validation required? → Yes
    │   ├── Disinfection validation required? → Yes
    │   └── Sterilization validation required?
    │       ├── Yes (critical) → Full sterilization validation
    │       └── No (semi-critical, HLD sufficient) → Disinfection validation only
    └── No (non-critical) → ISO 17664-2 applies
        ├── Cleaning validation required? → Yes (if soiled)
        └── Disinfection validation required? → Yes (if indicated)

Key Takeaways

1. ISO 17664-1 and ISO 17664-2 are harmonized under EU MDR and recognized by FDA — but FDA has partial recognition of Part 1 due to conflicts with its own guidance.

2. FDA requires separate cleaning validation data in premarket submissions — this is a key difference from most other regulators.

3. Worst-case device selection must be documented with rationale covering complexity, material, surface area, contamination accessibility, and load configuration.

4. Lifetime validation must demonstrate safety and performance across the maximum claimed number of reprocessing cycles.

5. Biocompatibility must be assessed in the ready-to-use state after maximum reprocessing cycles, including residual analysis.

6. IFU content must include specific, validated parameters — generic instructions referencing hospital policy are insufficient.

Sources

• ISO 17664-1:2021 — Processing of health care products — Information to be provided by the medical device manufacturer for the processing of medical devices — Part 1: Critical and semi-critical medical devices

• ISO 17664-2:2021 — Processing of health care products — Information to be provided by the medical device manufacturer for the processing of medical devices — Part 2: Non-critical medical devices

• FDA Guidance: Reprocessing Medical Devices in Health Care Settings: Validation Methods and Labeling (March 2015, amended June 2017)

• ANSI/AAMI ST98:2022 — Cleaning validation of health care products

• AAMI TIR12:2020/(R)2023 — Designing, testing, and labeling reusable medical devices for reprocessing

• ASTM F3208-20 — Standard Guide for Selecting Test Soils for Validation of Cleaning Methods

• FDA Recognized Consensus Standards Database — ISO 17664-1 (Standard ID 43302), ISO 17664-2 (Standard ID 43305)

• Emergo by UL — US FDA Reprocessing Expectations (March 2026)